Coagulation Factor IX Activity Assay, Plasma
Hemophilia B, also known as Christmas disease, is an inherited bleeding disorder caused by reduced activity of coagulation factor IX. The severity of clinical manifestations correlates with the degree of factor IX deficiency. Individuals with severe hemophilia B, defined by factor IX activity below 1%, typically present in early childhood, often before two years of age, with frequent spontaneous bleeding episodes involving joints, muscles, or soft tissues, as well as prolonged bleeding after minor trauma or procedures. Moderate hemophilia B, with activity levels between 1% and 5%, is associated with fewer spontaneous bleeds but significant bleeding following injury or surgery, usually recognized by early childhood. Mild hemophilia B, characterized by activity levels greater than 5% but below the lower limit of normal, may remain undiagnosed until adolescence or adulthood and often presented only after major trauma, surgery, or dental procedures.
Although hemophilia B is inherited in an X-linked manner and primarily affects males, a substantial proportion of heterozygous females exhibit reduced factor IX activity due to skewed X-chromosome inactivation. Approximately 30% of female carriers have activity levels below 40% and may experience abnormal bleeding, particularly in the setting of invasive procedures, childbirth, or trauma. Bleeding manifestations in hemophilia B include hemarthrosis, muscle hematomas, mucocutaneous bleeding, gastrointestinal or genitourinary hemorrhage, and, most seriously, intracranial hemorrhage. Recurrent joint bleeding can result in chronic arthropathy and functional impairment without adequate prophylactic therapy.
Laboratory evaluation begins with measurement of factor IX activity. Reduced activity supports the diagnosis and allows classification of disease severity. Molecular genetic testing of the F9 gene is used to confirm the diagnosis, identify the causative pathogenic variant, and enable carrier detection and family counseling.
- As an aid in the diagnosis of hemophilia B in patients with suspected inherited bleeding disorders
- Monitoring response to replacement therapy or prophylactic treatment
- Evaluation of prolonged activated partial thromboplastin time (aPTT) as part of a coagulation workup
Severe hemophilia B: <1% activity
Moderate hemophilia B: 1% to 5% activity
Mild hemophilia B: >5% to below the lower limit of normal
Factor IX activity may also be reduced in liver disease, vitamin K deficiency, disseminated intravascular coagulation, or during warfarin therapy. Results should be interpreted in conjunction with clinical findings, aPTT, mixing studies, and inhibitor testing when indicated.
Increased activity may be observed following factor IX replacement therapy, post-infusion peaks, or after successful gene therapy. Mild increases are rarely seen in inflammatory states.
≤6 months of age: ≥20%
6 months of age and adults: 65–140%
Platelet-poor plasma on 3.2% sodium citrate (Light-blue top) vial, 1 mL minimum.
Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or ideally, at or below -40 degrees C. Patient must not be receiving warfarin or heparin therapy.
Stability
- Ambient: up to 4 hours
- Refrigerated: unfavorable
- Frozen: 28 days
- IUBMB Life. 2025 May;77(5):e70024. [PMID: 40402203]
- Blood. 2024 Nov 21;144(21):2198-2210. [PMID: 38996207]
- Am J Clin Pathol. 2013 Nov;140(5):680-5. [PMID: 24124147]
- J Thromb Haemost. 2015 Jul;13(7):1184-95. [PMID: 25851415]
- GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. [PMID: 20301668]